AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2108575 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian Heart Association class
Number of subjects: 386
Study 375849 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (750 mg per day)
Number of subjects: 60
Study 375849 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) (3000 mg per day)
Number of subjects: 60
Study 30902579 — intervention group
Group type: EXPERIMENTAL
Intervention: Birthing ball
Number of subjects: 0
Study 30902579 — intervention group
Group type: COMPARATOR
Intervention: Pethidine and haloperidol (50mg and 2.5mg respectively)
Number of subjects: 0
Study 30902579 — intervention group
Group type: COMPARATOR
Intervention: Midwife subscale (both groups)
Number of subjects: 0
Study 29493562 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic blood pressure target of less than 120 mmHg)
Number of subjects: 9361
Study 29493562 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (systolic blood pressure target of less than 140 mmHg)
Number of subjects: 9361
Study 29493562 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 9361
Study 29493562 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 9361
Study 26767802 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 60
Study 26767802 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency venous ablation (RFA)
Number of subjects: 60
Study 25112584 — intervention group
Group type: EXPERIMENTAL
Intervention: naloxegol 25 mg/day
Number of subjects: 804
Study 25112584 — intervention group
Group type: COMPARATOR
Intervention: usual care (UC; investigator-chosen laxative regimen)
Number of subjects: 804
Study 25112584 — intervention group
Group type: COMPARATOR
Intervention: usual care (UC)
Number of subjects: 804
Study 22772353 — intervention group
Group type: EXPERIMENTAL
Intervention: Loupe visualization method
Number of subjects: 12
Study 22772353 — intervention group
Group type: EXPERIMENTAL
Intervention: Out of loupe visualization method
Number of subjects: 12
Study 22772353 — intervention group
Group type: EXPERIMENTAL
Intervention: Naked eye visualization method
Number of subjects: 12
Study 22772353 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased operating table height
Number of subjects: 12
Study 22772353 — intervention group
Group type: EXPERIMENTAL
Intervention: Loupe visualization method with optimal table height
Number of subjects: 12
Study 21045119 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training (experimental group)
Number of subjects: 64
Study 21045119 — intervention group
Group type: COMPARATOR
Intervention: General physical exercises (control group)
Number of subjects: 64
Study 17285414 — intervention group
Group type: EXPERIMENTAL
Intervention: HME at total flow of 2 lxmin(‐1) (group HME2L)
Number of subjects: 80
Study 17285414 — intervention group
Group type: COMPARATOR
Intervention: No HME at total flow of 2 lxmin(‐1) (group 2L)
Number of subjects: 80
Study 17285414 — intervention group
Group type: EXPERIMENTAL
Intervention: HME at total flow of 4 lxmin(‐1) (group HME4L)
Number of subjects: 80
Study 17285414 — intervention group
Group type: COMPARATOR
Intervention: No HME at total flow of 4 lxmin(‐1) (group 4L)
Number of subjects: 80
Study 17285414 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study 16182025 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone setting (5 weekly sessions)
Number of subjects: 42
Study 16182025 — intervention group
Group type: COMPARATOR
Intervention: Follow-up without therapy (Control)
Number of subjects: 42
Study 11821266 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal E2 cream 0.1 mg twice daily and vaginal progesterone gel
Number of subjects: 24
Study 11821266 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 50 mg
Number of subjects: 24
Study 11821266 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 100 mg
Number of subjects: 24
Study 10359475 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for Depressed Adolescents (IPT-A)
Number of subjects: 48
Study 10359475 — intervention group
Group type: COMPARATOR
Intervention: Clinical monitoring (Control)
Number of subjects: 48
Study 7623907 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 21772
Study 7623907 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrates
Number of subjects: 21772
Study 7623907 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting-enzyme inhibitors
Number of subjects: 21772
Study 7623907 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-channel blockers
Number of subjects: 21772
Study 7623907 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 21772
Study 7623907 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiography
Number of subjects: 21772
Study 7623907 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 21772
Study 7623907 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary-artery bypass surgery
Number of subjects: 21772
Study 7623907 — intervention group
Group type: COMPARATOR
Intervention: Angiography (New England)
Number of subjects: 21772
Study 7623907 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac procedures
Number of subjects: 21772
Study 2202552 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg flurbiprofen twice daily
Number of subjects: 106
Study 2202552 — intervention group
Group type: COMPARATOR
Intervention: 375 mg naproxen twice daily
Number of subjects: 106
Study 7128668 — intervention group
Group type: EXPERIMENTAL
Intervention: Amezinium 30 mg
Number of subjects: 6
Study 7128668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30977377 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone acetate provocative test
Number of subjects: 66
Study 30977377 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal triamcinolone acetonide
Number of subjects: 66
Study 31425640 — intervention group
Group type: EXPERIMENTAL
Intervention: Torque technique
Number of subjects: 124
Study 31425640 — intervention group
Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 124
Study 28949089 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (4 doses of 0.5 g/kg) and RTX (375 mg/m2)
Number of subjects: 25
Study 28949089 — intervention group
Group type: COMPARATOR
Intervention: Placebo (wrapped isovolumetric saline infusion)
Number of subjects: 25
Study 27788771 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation with continuous irrigation
Number of subjects: 40
Study 27788771 — intervention group
Group type: COMPARATOR
Intervention: Standard preparation
Number of subjects: 40
Study 27788771 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 24411144 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (weekly one hour sessions for eight weeks)
Number of subjects: 15
Study 24411144 — intervention group
Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 15
Study 23439632 — intervention group
Group type: EXPERIMENTAL
Intervention: IMT plus Roux‐en‐Y gastric bypass
Number of subjects: 60
Study 23439632 — intervention group
Group type: EXPERIMENTAL
Intervention: IMT plus sleeve gastrectomy
Number of subjects: 60
Study 23439632 — intervention group
Group type: COMPARATOR
Intervention: Intensive medical therapy (IMT) alone
Number of subjects: 60
Study 20609467 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg twice daily
Number of subjects: 54
Study 20609467 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 100 mg twice daily
Number of subjects: 54
Study 18476986 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week dietary weight loss intervention
Number of subjects: 57
Study 16846931 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (group A) for 3 months
Number of subjects: 60
Study 16846931 — intervention group
Group type: COMPARATOR
Intervention: Immunostimulating vaccine (group B) for 3 months
Number of subjects: 60
Study 16846931 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (patients without LPR symptoms)
Number of subjects: 60
Study 12797714 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 253
Study 12797714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 11147226 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatments in MRC Adult Leukaemia Trials
Number of subjects: 0
Study 11147226 — intervention group
Group type: EXPERIMENTAL
Intervention: Ph chromosome-positive ALL treatment
Number of subjects: 0
Study 11147226 — intervention group
Group type: EXPERIMENTAL
Intervention: STIs treatment
Number of subjects: 0
Study 8644595 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 14
Study 8644595 — intervention group
Group type: COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 14
Study 1594255 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture
Number of subjects: 30
Study 1594255 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 30
Study 6380261 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcainide, 100 mg twice daily
Number of subjects: 39
Study 6380261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 6380261 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcainide
Number of subjects: 39
Study 30776290 — intervention group
Group type: EXPERIMENTAL
Intervention: PES-guided PEEP
Number of subjects: 200
Study 30776290 — intervention group
Group type: COMPARATOR
Intervention: Empirical high PEEP-Fio2
Number of subjects: 200
Study 29258133 — intervention group
Group type: EXPERIMENTAL
Intervention: New DIN 6868-157 standard for quality assurance of diagnostic displays
Number of subjects: 0
Study 29258133 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily constancy test
Number of subjects: 0
Study 29258133 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical relevance of the new standard
Number of subjects: 0
Study 27755533 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 6537
Study 27755533 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (pre-diagnostic usage)
Number of subjects: 6537
Study 27755533 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 6537
Study 27755533 — intervention group
Group type: COMPARATOR
Intervention: Other antiarrhythmic drugs
Number of subjects: 6537
Study 24785663 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose in normal saline (D5NS)
Number of subjects: 0
Study 24785663 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 0
Study 21895371 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic endurance training (cycling)
Number of subjects: 68
Study 21895371 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonendurance training (stretching/coordination)
Number of subjects: 68
Study 21895371 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 68
Study 20484451 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (25 mg zinc/d in addition to 60 mg iron and 250 microg folic acid)
Number of subjects: 184
Study 20484451 — intervention group
Group type: COMPARATOR
Intervention: Control group (iron and folic acid only)
Number of subjects: 184
Study 17289291 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 601
Study 16040667 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (AC)
Number of subjects: 327
Study 16040667 — intervention group
Group type: COMPARATOR
Intervention: No decontamination (Control)
Number of subjects: 327
Study 12390375 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive papertape
Number of subjects: 140
Study 12390375 — intervention group
Group type: EXPERIMENTAL
Intervention: Octylcyanoacrylate
Number of subjects: 140
Study 12390375 — intervention group
Group type: EXPERIMENTAL
Intervention: Poliglecaprone
Number of subjects: 140
Study 10445416 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg per day for 10 days)
Number of subjects: 31
Study 10445416 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (diet, corsil)
Number of subjects: 31
Study 7598769 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-derived HB vaccine with yellow fever vaccine
Number of subjects: 0
Study 7598769 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant HB vaccine with yellow fever vaccine
Number of subjects: 0
Study 7598769 — intervention group
Group type: EXPERIMENTAL
Intervention: Polio vaccine with plasma-derived HB vaccine
Number of subjects: 0
Study 7598769 — intervention group
Group type: EXPERIMENTAL
Intervention: Polio vaccine with recombinant HB vaccine
Number of subjects: 0
Study 7598769 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of all vaccines
Number of subjects: 0
Study 2262356 — intervention group
Group type: COMPARATOR
Intervention: Group A - 60Co 60 Gy in 30 fractions
Number of subjects: 859
Study 2262356 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B - 60Co 70.4 Gy in 64 fractions
Number of subjects: 859
Study 2262356 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C - 60Co 60 Gy in 30 fractions plus chemotherapy (5 Fu, 250 mg/m2/IV every 2 days)
Number of subjects: 859
Study 2262356 — intervention group
Group type: COMPARATOR
Intervention: Group B and C compared to Group A
Number of subjects: 859
Study 2262356 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 859
Study 902232 — intervention group
Group type: EXPERIMENTAL
Intervention: Methanol extraction residue (MER) of Bacille‐Calmette‐Guerin (BCG) in addition to radiotherapy and/or chemotherapy
Number of subjects: 51
Study 902232 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy and/or chemotherapy alone
Number of subjects: 51
Study 902232 — intervention group
Group type: EXPERIMENTAL
Intervention: Methanol extraction residue (MER) of Bacille‐Calmette‐Guerin (BCG)
Number of subjects: 51
Study 31646724 — intervention group
Group type: EXPERIMENTAL
Intervention: Gla-300
Number of subjects: 929
Study 31646724 — intervention group
Group type: COMPARATOR
Intervention: IDeg-100
Number of subjects: 929
Study 30420192 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar Locking Plate (VLP)
Number of subjects: 118
Study 30420192 — intervention group
Group type: COMPARATOR
Intervention: External Fixation (EF)
Number of subjects: 118
Study 28151886 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 233
Study 28151886 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-optic laryngoscopy (FOL)
Number of subjects: 233
Study 25826870 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (5% solution, 20 ml/day for 20 days)
Number of subjects: 99
Study 25826870 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin (10 ml intravenously, twice a day for 10 days)
Number of subjects: 99
Study 25826870 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin (20 ml/day for first 10 days, 10 ml/day for next 10 days)
Number of subjects: 99
Study 23768799 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity functional exercise program
Number of subjects: 48
Study 23768799 — intervention group
Group type: COMPARATOR
Intervention: Control activity
Number of subjects: 48
Study 16405547 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 1115
Study 16405547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1115
Study 16405547 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor papilla sphincterotomy
Number of subjects: 1115
Study 16405547 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspected sphincter of Oddi dysfunction (SOD)
Number of subjects: 1115
Study 16405547 — intervention group
Group type: EXPERIMENTAL
Intervention: History of post-ERCP pancreatitis
Number of subjects: 1115
Study 16405547 — intervention group
Group type: EXPERIMENTAL
Intervention: Age <60 years
Number of subjects: 1115
Study 16405547 — intervention group
Group type: EXPERIMENTAL
Intervention: >=2 contrast injections into the pancreatic duct
Number of subjects: 1115
Study 16405547 — intervention group
Group type: EXPERIMENTAL
Intervention: Trainee involvement
Number of subjects: 1115
Study 15380456 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg daily)
Number of subjects: 131
Study 15380456 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg daily)
Number of subjects: 131
Study 15380456 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofibrate (100 mg daily)
Number of subjects: 131
Study 15380456 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg daily)
Number of subjects: 131
Study 15380456 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (n = 59)
Number of subjects: 131
Study 10734016 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 microgram/kg IL-10 subcutaneously daily for 90 days
Number of subjects: 24
Study 10734016 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 microgram/kg IL-10 subcutaneously daily for 90 days
Number of subjects: 24
Study 8736999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol exposure in HR subjects
Number of subjects: 0
Study 8736999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol exposure in C57BL/6 mice (analogous to HR human subjects)
Number of subjects: 0
Study 8736999 — intervention group
Group type: COMPARATOR
Intervention: Comparison of opioid receptor density in C57BL/6 mice and DBA/2 mice
Number of subjects: 0
Study 8736999 — intervention group
Group type: COMPARATOR
Intervention: Comparison of opioid receptor density in AA rats and ANA rats
Number of subjects: 0
Study 8736999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol exposure in ethanol-preferring animals
Number of subjects: 0
Study 1551151 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled lumbar epidural (PCA-E) fentanyl
Number of subjects: 34
Study 1551151 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous (PCA-i.v.) fentanyl
Number of subjects: 34
Study 3926511 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusions
Number of subjects: 12
Study 3926511 — intervention group
Group type: COMPARATOR
Intervention: Saline infusions
Number of subjects: 12
Study 31524303 — intervention group
Group type: EXPERIMENTAL
Intervention: Shame mood induction group
Number of subjects: 38
Study 31524303 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 30700364 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior approach surgery
Number of subjects: 84
Study 30700364 — intervention group
Group type: COMPARATOR
Intervention: Anterior approach surgery
Number of subjects: 84
Study 29061618 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus additional in-bed cycling sessions
Number of subjects: 68
Study 29061618 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 68
Study 25740265 — intervention group
Group type: EXPERIMENTAL
Intervention: QMF149 150/80 μg
Number of subjects: 48
Study 25740265 — intervention group
Group type: EXPERIMENTAL
Intervention: QMF149 150/320 μg
Number of subjects: 48
Study 25740265 — intervention group
Group type: EXPERIMENTAL
Intervention: Both QMF149 doses
Number of subjects: 48
Study 24967423 — intervention group
Group type: EXPERIMENTAL
Intervention: Levitan FPS optical stylet
Number of subjects: 79
Study 24967423 — intervention group
Group type: COMPARATOR
Intervention: Lary-Flex videolaryngoscope
Number of subjects: 79
Study 21849557 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticospinal excitability assessed using single-pulse transcranial magnetic stimulation (TMS) over the upper-arm region of M1 (primary motor cortex) during movements with resistive interaction torques.
Number of subjects: 12
Study 21849557 — intervention group
Group type: COMPARATOR
Intervention: Corticospinal excitability assessed using single-pulse transcranial magnetic stimulation (TMS) over the upper-arm region of M1 (primary motor cortex) during movements with assistive interaction torques.
Number of subjects: 12
Study 19138537 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated measurement of joint space width (JSW) using a novel software program
Number of subjects: 50
Study 19138537 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated measurement of joint space narrowing (JSN) using a novel software program
Number of subjects: 50
Study 19138537 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity to change of JSW
Number of subjects: 50
Study 19138537 — intervention group
Group type: EXPERIMENTAL
Intervention: Observer intervention for computer measurement
Number of subjects: 50
Study 17472415 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin
Number of subjects: 685
Study 17472415 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin at a dose of 32 mg/day
Number of subjects: 685
Study 15451153 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker ON
Number of subjects: 29
Study 11361052 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (625 mg bid orally)
Number of subjects: 31
Study 11361052 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (150 mg tid orally)
Number of subjects: 31
Study 11361052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 11361052 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid and Moclobemide
Number of subjects: 31
Study 10345150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (EGb 761) 80 mg twice daily
Number of subjects: 44
Study 10345150 — intervention group
Group type: COMPARATOR
Intervention: Betahistine dihydrochloride (BI) 16 mg twice daily
Number of subjects: 44
Study 7537666 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastron (strontium‐89 chloride)
Number of subjects: 29
Study 7537666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 2497633 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh yogurt ingestion
Number of subjects: 10
Study 2497633 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated yogurt ingestion
Number of subjects: 10
Study 2497633 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro yogurt at pH 5.0
Number of subjects: 10
Study 31418811 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk On! (WO) intervention
Number of subjects: 2707